3 Cathie Wood Stocks for a $150 Billion Market That's Just Forming

Cathie Wood has gained notoriety from making some seemingly outlandish calls on stocks and for being right. Her company's extrapolation of real world data and technological trends has proved to be an incredibly profitable investing strategy, even after some recent turbulence.

One of her less controversial projections is around preventative cancer screening. Specifically, she and her team believe liquid-biopsy screening for cancer could grow to a $150 billion market as the cost of tests drop.

The thinking is that early screening is the best way to save lives, since all solid tumors progress from treatable and local to lethal and metastatic. The falling cost of sequencing the human genome has introduced many new use cases, and the U.S. health system will likely adopt routine screening as costs drop below $1,000. If the projection proves true, three of her portfolio's companies -- Pacific Biosciences (NASDAQ: PACB), Guardant Health (NASDAQ: GH), and Exact Sciences (NASDAQ: EXAS) -- could be big winners.